Our lead T-cell therapy targets the NY-ESO peptide which is present across multiple cancer types. The NY-ESO TCR targets the NY-ESO-1 target peptide on cancer cells. NY-ESO-1 is one of the best-characterized and most immunogenic cancer testis antigens, and is frequently expressed by tumors of different origins and in advanced tumors.
In the U.S. we are conducting multiple Phase 1/2 clinical trials for our NY-ESO TCR therapeutic candidate in patients with solid tumors and hematological malignancies including synovial sarcoma, multiple myeloma, melanoma, NSCLC and ovarian cancer. We have seen responses and evidence of tumor reduction in patients with both synovial sarcoma and multiple myeloma. The initial data also suggests a promising risk/benefit profile. We continue to expand our clinical trials in the U.S. Submissions have also been made to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom and to Health Canada, which has now approved the clinical trial application.
We are developing our NY-ESO TCR therapeutic candidate in partnership with GSK. Read more about our strategic collaboration with GSK.